The European Medicines Agency (EMA) has recommended granting marketing authorization to the combined influenza and COVID-19 messenger RNA (mRNA) vaccine, mCombriax (Moderna), for people aged 50 years ...
The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...
Moderna’s messenger RNA influenza vaccine succeeded in two pivotal clinical trials, but the Food and Drug Administration is refusing to even review the application seeking regulatory approval, telling ...
The Food and Drug Administration rattled the biotech industry last week when it said it wouldn't even look at Moderna's application to market the first mRNA flu shot. But on Wednesday, the agency ...
Washington — U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a ...
The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results